Opendata, web and dolomites

SAFE-CAB SIGNED

Laser-Assisted Surgical System to Revolutionize Cardiac Bypass Surgeries

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SAFE-CAB project word cloud

Explore the words cloud of the SAFE-CAB project. It provides you a very rough idea of what is the project "SAFE-CAB" about.

surgery    accelerate    hemex    survival    professional    translates    training    final    patient    suturing    solutions    89m    gt    readiness    700    first    catheter    annual    disease    validation    lt    substantially    patients    replace    risk    berlin    arrested    recovery    opportunity    medical    cab    192m    cardiovascular    company    rates    arresting    surgeries    organisation    group    outcomes    approval    containing    hospital    regulatory    thereby    seeking    attack    artery    kit    prevent    proprietary    technically    invasive    complemented    surgeons    extremely    clinical    safe    myocardial    chest    pan    herzzentrum    deutsches    surgical    closed    annually    beating    coronary    entry    implant    standard    shorter    heart    treat    market    laser    care    vision    minimally    15    cardiac    replacing    endovascular    times    obtain       oldest    society    infarction    performed    flow    lifetec    health    complications    reduce    assisted    amt    bypass    sme    severe    realize    dutch    device    blood    procedure   

Project "SAFE-CAB" data sheet

The following table provides information about the project.

Coordinator
AMT MEDICAL RESEARCH BV 

Organization address
address: YALELAAN 52
city: UTRECHT
postcode: 3584 CM
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 2˙850˙312 €
 EC max contribution 2˙182˙118 € (77%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-FTI-2018-2020
 Funding Scheme IA
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2022-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AMT MEDICAL RESEARCH BV NL (UTRECHT) coordinator 397˙250.00
2    HEMEX AG CH (LIESTAL) participant 903˙875.00
3    DEUTSCHES HERZZENTRUM BERLIN DE (BERLIN) participant 432˙625.00
4    LIFETEC GROUP BV NL (EINDHOVEN) participant 257˙993.00
5    EUROPEAN SOCIETY FOR CARDIOVASCULAR AND ENDOVASCULAR SURGERY CH (ZURICH) participant 190˙375.00

Map

 Project objective

Coronary Artery Bypass (CAB) surgery is performed annually in >700,000 patients to treat coronary artery disease and prevent myocardial infarction (heart attack). Standard CAB surgery involves a highly invasive open-heart procedure in arrested/non-beating heart, that is associated with long recovery times and severe complications. The surgeons are seeking for less invasive, closed chest CAB procedures on beating heart, but current solutions are technically extremely challenging and thereby only used in <1-3% of all surgeries. The vision of the SAFE-CAB consortium is to make the minimally invasive CAB surgeries available to all surgeons as a novel standard of care, thereby substantially improve patient outcomes and reduce health care costs. The goal of the project is to bring to market a first-of-its-kind laser-assisted minimally invasive surgical system (surgical kit containing surgical implant and laser catheter). SAFE-CAB enables minimally invasive procedure on beating heart, without the need for arresting blood flow or complex hand suturing. With shorter recovery times, less complications and improved survival rates in high-risk patients, the SAFE-CAB technology has a potential to replace high-risk open-heart surgeries. Replacing only 15% of open-heart surgeries in Europe and US translates to annual market opportunity of >€89M and >€192M. Dutch SME AMT Medical has developed the proprietary SAFE-CAB technology to clinical readiness. To substantially accelerate the market entry of the product, the company partners with a leading European cardiac surgery hospital Deutsches Herzzentrum Berlin and a pan-European clinical/regulatory medical device company HEMEX to obtain regulatory approval through final clinical validation . To realize European wide-implementation, the consortium is complemented by a surgery training company LifeTec Group and the oldest professional organisation for cardiac surgeons European Society of CardioVascular and Endovascular Surgery.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SAFE-CAB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SAFE-CAB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)

PAV-DT (2019)

A disruptive technology that enables low cost real-time monitoring of road pavement condition by any ordinary vehicle circulating on the road, and automatically designs plans for predictive maintenance.

Read More  

Bio-LP-1 (2020)

A novel rapid environmental test for the human pathogen Legionella

Read More  

DERMAREP (2019)

Clinical validation and production upscaling of a novel product for healing of Pressure Ulcers, Leg Ulcers and Diabetic Foot Ulcers.

Read More